Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences

Alpine Immune Sciences (NASDAQ: ALPN) will participate in two healthcare conferences this March.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

02/28/2023 - 04:33 PM

SEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will participate in two upcoming healthcare conferences.

Tuesday, March 7^th at 10:30am ET/7:30am PT, the Company will take part in a corporate panel discussion on autoimmune and inflammatory diseases and host investor meetings at the 46^th Annual Cowen Healthcare Conference
Tuesday, March 14^th at 3:20pm ET/12:20 pm PT, the Company will participate in a fireside chat and host investor meetings at the 33^rd Annual Oppenheimer Healthcare Conference.

Live webcasts of the presentations will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and replays will be available on the Company's website for 90 days following the live events.

About Alpine Immune Sciences

Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com and follow us on Twitter and LinkedIn.